PolyPid (PYPD) Competitors $3.40 -0.02 (-0.58%) Closing price 09/4/2025 03:59 PM EasternExtended Trading$3.35 -0.05 (-1.47%) As of 09/4/2025 06:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PYPD vs. STIM, INGN, INFU, CVRX, KRMD, MBOT, CV, ELMD, BSGM, and PDEXShould you be buying PolyPid stock or one of its competitors? The main competitors of PolyPid include Neuronetics (STIM), Inogen (INGN), InfuSystem (INFU), CVRx (CVRX), KORU Medical Systems (KRMD), Microbot Medical (MBOT), CapsoVision (CV), Electromed (ELMD), Biosig Technologies (BSGM), and Pro-Dex (PDEX). These companies are all part of the "medical equipment" industry. PolyPid vs. Its Competitors Neuronetics Inogen InfuSystem CVRx KORU Medical Systems Microbot Medical CapsoVision Electromed Biosig Technologies Pro-Dex Neuronetics (NASDAQ:STIM) and PolyPid (NASDAQ:PYPD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, valuation and media sentiment. Which has preferable earnings & valuation, STIM or PYPD? PolyPid has lower revenue, but higher earnings than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeuronetics$74.89M2.92-$43.71M-$1.13-2.93PolyPidN/AN/A-$29.02M-$3.83-0.89 Is STIM or PYPD more profitable? PolyPid has a net margin of 0.00% compared to Neuronetics' net margin of -43.47%. Neuronetics' return on equity of -156.36% beat PolyPid's return on equity.Company Net Margins Return on Equity Return on Assets Neuronetics-43.47% -156.36% -35.69% PolyPid N/A -453.95%-138.92% Do insiders and institutionals hold more shares of STIM or PYPD? 53.6% of Neuronetics shares are held by institutional investors. Comparatively, 26.5% of PolyPid shares are held by institutional investors. 8.7% of Neuronetics shares are held by company insiders. Comparatively, 24.7% of PolyPid shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Do analysts rate STIM or PYPD? Neuronetics presently has a consensus target price of $7.00, suggesting a potential upside of 111.48%. PolyPid has a consensus target price of $12.40, suggesting a potential upside of 264.71%. Given PolyPid's stronger consensus rating and higher possible upside, analysts clearly believe PolyPid is more favorable than Neuronetics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neuronetics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00PolyPid 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Does the media prefer STIM or PYPD? In the previous week, PolyPid had 3 more articles in the media than Neuronetics. MarketBeat recorded 7 mentions for PolyPid and 4 mentions for Neuronetics. Neuronetics' average media sentiment score of 1.40 beat PolyPid's score of 0.52 indicating that Neuronetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neuronetics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PolyPid 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, STIM or PYPD? Neuronetics has a beta of 1.28, suggesting that its stock price is 28% more volatile than the S&P 500. Comparatively, PolyPid has a beta of 1.48, suggesting that its stock price is 48% more volatile than the S&P 500. SummaryPolyPid beats Neuronetics on 10 of the 16 factors compared between the two stocks. Get PolyPid News Delivered to You Automatically Sign up to receive the latest news and ratings for PYPD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PYPD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PYPD vs. The Competition Export to ExcelMetricPolyPidMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$54.37M$2.55B$5.75B$9.85BDividend YieldN/A49.35%6.67%4.51%P/E Ratio-0.8922.9075.9926.43Price / SalesN/A714.55546.95119.09Price / CashN/A169.7737.0558.92Price / Book4.535.3910.916.06Net Income-$29.02M$32.95M$3.29B$266.28M7 Day Performance1.49%1.08%0.18%-0.32%1 Month Performance0.89%6.32%6.26%3.44%1 Year Performance-1.16%-0.28%51.55%23.11% PolyPid Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PYPDPolyPid2.5568 of 5 stars$3.40-0.6%$12.40+264.7%-2.6%$54.37MN/A-0.8980Positive NewsShort Interest ↑STIMNeuronetics2.142 of 5 stars$3.22+0.5%$7.00+117.7%+302.5%$212.58M$74.89M-2.85180Positive NewsINGNInogen4.0282 of 5 stars$7.70-0.1%$11.00+42.9%-29.9%$207.40M$335.70M-7.241,030Positive NewsINFUInfuSystem2.5243 of 5 stars$9.80-0.8%$12.50+27.6%+72.8%$200.38M$139.89M163.53410Positive NewsCVRXCVRx1.9906 of 5 stars$7.51+0.7%$14.00+86.5%-13.0%$196.13M$51.29M-3.57160Positive NewsKRMDKORU Medical Systems2.7697 of 5 stars$4.21+0.1%$4.63+10.0%+70.1%$194.21M$33.65M-46.6780Positive NewsMBOTMicrobot Medical2.0222 of 5 stars$4.14-0.5%$9.00+117.5%+305.3%$188.81MN/A-7.1520CVCapsoVisionN/A$3.99flat$5.50+37.8%N/A$186.61MN/A0.0090News CoverageELMDElectromed3.0471 of 5 stars$20.40+1.0%$33.50+64.3%+49.3%$171.03M$61.44M27.19160BSGMBiosig Technologies1.6374 of 5 stars$5.44+2.6%$10.00+83.8%+916.5%$168.07M$40K0.0050PDEXPro-Dex2.5192 of 5 stars$46.35+0.3%$56.00+20.8%+107.0%$151.09M$53.84M16.55140News CoverageEarnings Report Related Companies and Tools Related Companies Neuronetics Alternatives Inogen Alternatives InfuSystem Alternatives CVRx Alternatives KORU Medical Systems Alternatives Microbot Medical Alternatives CapsoVision Alternatives Electromed Alternatives Biosig Technologies Alternatives Pro-Dex Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PYPD) was last updated on 9/5/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PolyPid Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share PolyPid With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
